CSI Market
Sign In | Register

Akoya Biosciences Inc (AKYA) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access AKYA quarterly Cash Flow →
Quarterly cash flow trends provide additional context on Akoya Biosciences Inc's liquidity and ability to support ongoing operations and capital needs.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2024)
12 Months 		(Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-55.37
Depreciation & amortization7.65
Amortization of Other Assets0.93
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability2.46
Provision For Loan Losses Expensed0.92
Increase (Decrease) in Inventories-9.86
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation9.31
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Investment Income Amortization Of Discount-1.66
Increase Decrease In Operating Lease Liabilities-2.26
Operating Lease Adjustment2.04
Change In Inventory Reserve Adjustment3.50
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable2.30
Increase (Decrease) in Accounts Payable-3.02
Increase (Decrease) in Accrued Liabilities-1.32
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.53
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-0.26
Discontinued operations0.00
Net Cash flow from Operating Activities-44.10
Investing Activities
Capital Expenditures-2.46
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities11.90
Payments to Acquire Marketable Securities-104.29
Real Estate Investments0.00
Maturities Of Payments To Acquire Marketable Securities-
Maturities Of Marketable Securities70.80
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-24.05
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.09
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-2.12
Finance Lease Principal Payments-1.02
Proceeds From Issuance Initial Public Offering Net Of Offering Costs-
Refunds From Payments Of Accrued Termination Fees-
Refunds From Payments Of Deferred Offering Costs-0.15
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-3.21
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-46.56
Total Cash Flow-71.36
4 historic quarters locked

Sign in to unlock the full Akoya Biosciences Inc cash flow history.

Sign In Create Free Account

About Akoya Biosciences Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001558370-25-003124

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License